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Abstract:  Objective: This study was designed to demonstrate that four weeks of fluticasone propionate (FP) 100 
micrograms (mcg) combined with salmeterol 50 mcg twice daily (BID) via DISKUS
® resulted in protection against 
bronchospasm induced by activity, as measured by standardized exercise challenge testing in pediatric and adolescent 
subjects who required regular use of inhaled corticosteroids for the treatment of persistent asthma. 
Methods: Prior to study entry, all patients reported regular use of inhaled corticosteroids (ICS). During screening all 
patients demonstrated 20% fall in FEV1 following exercise. 
Results: A total of 231 subjects aged 4 to 17 were randomized to the two study treatments: 113 to the FP/salmeterol 
combination group (FSC) and 118 to receive FP 100 mcg BID. Of the subjects randomized, 106 (94%) subjects in the 
FSC 100/50 group and 108 (92%) subjects in the FP 100 group completed the study. At the end of treatment (Week 4), 
both FSC and FP protected against a fall in FEV1 following exercise in patients who at baseline experienced 20% fall in 
FEV1 following exercise. A mean decrease in FEV1 of 9.9% was observed in the FSC 100/50 group as compared with a 
mean decrease of 11.1% in the FP 100 group; there was no statistical difference between treatments. 
Conclusion: Both FSC 100/50 and FP 100 provided protection against an exercised-induced fall in FEV1; but statistically 
significant differences we not noted. Both treatments were well-tolerated over four weeks and FSC 100/50 had an adverse 
event profile comparable to that observed with FP 100. 
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INTRODUCTION 
  Current asthma treatment guidelines by the National 
Institutes of Health recommend the use of inhaled 
corticosteroids (ICS) as the preferred treatment in children 
and adults with persistent asthma who remain symptomatic 
despite the use of regular or as-needed short-acting beta2-
agonist monotherapy [1]. For many patients with 
symptomatic asthma, it is not uncommon for physical 
exertion to be the initial or only precipitating factor for acute 
symptoms of asthma. For example, it has been estimated that 
exercise is a trigger for acute bronchoconstriction in 
approximately 70% to 80% of patients with clinically 
diagnosed asthma [2]. And since it can occur in patients who 
otherwise have minimal or no asthma symptoms, exercise-
induced asthma (EIA) or exercise-induced bronchospasm 
(EIB) is often managed as a discrete entity. For these types 
of patients, salmeterol has been shown to be effective in 
protection against EIB for up to 12 hours [3, 4]. However, in 
patients who also have symptoms of persistent asthma, 
exercise or other forms of activity may represent only one of 
many stimuli or triggers that lead to worsening symptoms. 
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  Controller medications that improve the overall control 
of asthma in subjects with persistent asthma may also 
prevent or reduce asthma symptoms associated with daily 
physical activity or exercise. In this regard, chronic treatment 
with ICS has been shown to reduce the severity of exercise-
induced asthma symptoms [5, 6]. Similarly, the use of 
fluticasone propionate (FP) 100 micrograms (mcg) in 
combination with salmeterol 50 mcg has been shown to be 
effective in both improving asthma control and reducing 
asthma symptoms induced by activity in patients age 12 
years and older [7, 8]. 
  There are little data available comparing the 
FP/salmeterol combination (FSC) product with FP alone, 
with respect to the ability to attenuate symptoms of asthma 
that are triggered by activity in pediatric and adolescent 
patients with persistent asthma. Therefore, this study, using 
standardized exercise challenge tests, evaluated the efficacy 
of regular use of the FSC 100/50 mcg twice daily (BID) 
compared with FP 100 mcg BID for the prevention of 
bronchospasm triggered by activity in pediatric and 
adolescent subjects with persistent asthma who also 
experience activity-induced bronchospasm. 
MATERIALS AND METHODOLOGY 
  This study was a four-week, randomized, double-blind, 
parallel group, multi-center clinical trial (SFA100316). The 12    The Open Respiratory Medicine Journal, 2011, Volume 5  Murray et al. 
protocol and subject consent forms were approved by the 
respective Institutional Review Boards at all participating 
investigative sites and conducted in compliance with Good 
Clinical Practices. The study was identical to a duplicate 
study and detailed inclusion/exclusion criteria, methods and 
procedures, including exercise challenge and serial forced 
expiratory volume in once second (FEV1), have been 
previously reported [9]. 
Hypothesis 
  To demonstrate that FSC 100/50 mcg BID provided 
long-term protection against bronchospasm induced by 
activity in pediatric and adolescent subjects with persistent 
asthma and who also experienced activity-induced 
bronchospasm. 
Inclusion Criteria 
  1) Age 4-17 years of age; 2) Diagnosis of persistent 
asthma treated with daily ICS for at least four weeks; 3) 
FEV1 of 70 to 95% of predicted based on Polgar predicted 
normal values [10]; 4) Decrease in FEV1 of at least 15% 
after exercise challenge. 
Exclusion Criteria 
  1) history of life-threatening asthma; asthma hospitalization 
within six months of screening; 2) significant concurrent 
diseases, including a recent respiratory tract infection (within 
four weeks prior to screening); 3) pregnancy and/or lactation; 4) 
use of oral or parenteral corticosteroids within four weeks of 
screening or two courses of oral or parenteral corticosteroids 
within six months of screening; 5) use of the following 
medications within two weeks prior to screening and throughout 
the study: inhaled cromolyn, nedocromil, leukotriene modifiers, 
long-acting beta2-agonists, theophylline products, and inhaled 
anticholinergics. 
Outcomes 
  The primary measure of efficacy was maximal percent 
fall in FEV1 following exercise challenge. The secondary 
measure of efficacy was 4-hour serial post-dose FEV1 AUC 
on Treatment Day 1. Related efficacy measures included 
morning (AM) peak expiratory flow (PEF), evening (PM) 
PEF, percent of rescue-free days, and percent of symptom-
free days. 
Study Protocol 
Study Randomization Criteria 
  Upon study entry, subjects were switched from their pre-
study ICS to FP 100 mcg BID (Flovent DISKUS, 
GlaxoSmithKline, Research Triangle Park, North Carolina) 
and had to maintain their FEV1 at 70-95%. To be 
randomized to treatment, subjects were required to have 
documented albuterol use and/or asthma symptoms during 
the seven days immediately prior to the study visit, while 
receiving FP 100 mcg BID. 
Patient Recorded Measurements and Requirements 
Pertaining to Exercise Challenge 
  Electronic diary devices were used to record daytime and 
nighttime asthma symptoms on a 0- to 5-point Likert scale: 0 
represented no symptoms and 5 represented severe 
symptoms. Subjects also recorded AM and PM PEF (best of 
three attempts) and albuterol (Ventolin HFA, 
GlaxoSmithKline, Research Triangle Park, North Carolina; 
albuterol HFA, IVAX, Miami, Florida) used for relief of 
asthma symptoms. 
  A minimum 20% fall in baseline FEV1 following 
exercise challenge was also required at the end of the run-in 
period, as recommended by the Food and Drug 
Administration’s Draft Guidance for Industry Exercise-
Induced Bronchospasm (EIB)- Development of Drugs to 
Prevent EIB [11]. 
Treatment Randomization Criteria 
  Subjects meeting both asthma symptom and exercise 
challenge randomization criteria were assigned to receive 
one of the following treatments for four weeks in double-
blind fashion: FSC 100/50 mcg BID or FP 100 mcg BID via 
the DISKUS device. Serial FEV1 was measured in the clinic 
over four hours following the first dose of study medication, 
and exercise challenges were repeated after four weeks of 
treatment. 
Exercise Challenge 
  The exercise challenge, which followed a widely 
accepted and validated approach, consisted of running on a 
treadmill and determining the speed and incline of the 
treadmill that allowed the subject's heart rate to reach 80% 
of maximum based upon their age [12]. Heart rate was 
monitored continuously throughout the exercise challenge 
and room temperature was maintained between 20 to 25 
degrees Celsius (68 to 77 degrees Fahrenheit). To control for 
effects of temperature and humidity during exercise, subjects 
inspired compressed air from a balloon-reservoir bag fitted 
with a two-way, non-rebreathing valve and a mouthpiece or 
face mask. The treadmill incline did not exceed 15%, and 
subjects were required to refrain from holding onto the 
support railings during the exercise challenge. Subjects 
exercised for approximately two minutes under minimal 
conditions (Step I), approximately two more minutes under 
more strenuous conditions (Step II), and then  six minutes 
under the target conditions (Step III). Progression between 
steps was contingent upon the absence of cardiovascular and 
pulmonary signs and symptoms. Step III was stopped prior 
to the full six minutes if asthma symptoms were considered 
severe enough to warrant discontinuation of exercising. 
  The heart rate recovery time, defined as the time required 
to return within 5% of the pre-exercise FEV1 from the time 
of the maximal fall in FEV1 post-exercise was also collected 
during exercise challenge. 
Sample Size Calculation 
  It was estimated that 103 patients per treatment arm 
would provide 90% power to detect a difference of 5 
percentage points in the maximal percent fall in FEV1 
between the two treatments. The maximal percent fall in 
FEV1 was calculated as the percent change from pre-exercise 
FEV1 to the minimum FEV1 collected within one hour 
following exercise challenge. The primary population for all 
statistical analyses was the intent-to-treat (ITT) population. 
The ITT population consisted of all patients who were 
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sided hypothesis of no difference between treatment groups 
at a significance level of 0.05. An analysis of covariance 
(ANCOVA) model, (SAS version. 8.2, SAS Institute, Cary, 
North Carolina) including terms for treatment, pooled 
investigator, age stratum, and baseline, was used to test 
statistical differences between treatment groups for the FEV1 
and diary measures. 
  The protocol and subject consent forms were approved 
by the respective Institutional Review Boards at all 
participating sites and conducted in compliance with Good 
Clinical Practice. Written informed consent was obtained 
from each subject’s parent and/or legal guardian prior to 
enrollment and before conduct of any study procedures. 
RESULTS 
  Patients screened for the study reported using ICS for at 
least 28 days prior to screening at a daily dosage of no more 
than: 264 mcg of FP metered-dose inhaler (MDI), 600 mcg 
of budesonide, 504 mcg of beclomethasone dipropionate, 
1000 mcg of flunisolide, or 1000 mcg of triamcinolone 
acetonide. A total of 707 subjects were screened for the 
study; the majority of screen failures were due to inability to 
demonstrate the required drop of FEV1 following exercise 
challenge. A total of 231 subjects were randomized to the 
two study treatments: 113 to the FSC 100/50 group and 118 
to FP 100. Of those randomized, 106 (94%) subjects in the 
FSC 100/50 group and 108 (92%) subjects in the FP 100 
group completed the study (Fig. 1). 
 
Fig. (1). Number of patients screened, and number of subjects 
enrolled, randomized, completed, and withdrawn. 
  Baseline demographics were similar between the two 
treatment groups (Table 1). Pulmonary function, including 
FEV1, FEV1 % predicted, % reversibility, PEF, PEF % 
predicted, and ICS total daily dose were comparable as well. 
  Seven (6%) and ten (8%) subjects were discontinued in 
the FSC 100/50 and FP 100 groups, respectively (Table 2). 
Reasons for discontinuation included adverse event, consent 
withdrawn, lost to follow up, protocol violation, and asthma 
exacerbation. 
  Treatment compliance was assessed only during the 
treatment period according to the drug accountability 
conducted by the site personnel at each visit. Compliance 
with study medication was high and was similar across both 
groups. For the FSC 100/50 group compliance was 95.9% 
and the FP 100 group was 96.7%. 
Table  1.  Baseline Subject Demographic and Pulmonary 
Function Characteristics 
 
  FSC 100/50  FP 100 
Number 113  118 
Age, years   11.4 ± 3.42  11.7 ± 3.43 
Gender, Female % / Male %  42 / 58  44 / 56 


















Height, cm   150.0 ± 18.11  150.9 ± 17.88 
Weight, kg   49.49 ± 19.62  51.7 ± 19.155 
ICS total daily dose prior to study, mcg   195.4 ± 114.33  212.0 ± 114.97 
FEV1, L   2.17 ± 0.696  2.19 ± 0.703 
FEV1 % predicted   83.4 ± 6.61  83.5 ± 6.56 
% Reversibility   14.5 ± 15.75  11.8 ± 9.50 
PEF, L/second   4.55 ± 1.577  4.61 ± 1.633 
PEF, % predicted   77.4 ± 14.72  78.1 ± 14.55 
Gender and Ethnic Origin expressed as %; all other data expressed as mean ± standard 
deviation. 
Statistical testing was not performed on baseline characteristics. 
 
Table 2.  Reasons for Discontinuation from the Study 
 
  FSC 100/50  FP 100  
Adverse event  1 (<1)  1 (<1) 
Consent withdrawn  0  1 (<1) 
Lost to follow-up  0  2 (2) 
Protocol violation  3 (3)  4 (3) 
Asthma exacerbation  2 (2)  1 (<1) 
Other  1 (<1)  1 (<1) 
Data expressed as number (% of total). 
 
  Pre-exercise challenge FEV1 values were 2.27 ± 0.073 
liters (L) for FSC 100/50 and 2.24 ± 0.077 L for FP 100. No 
significant difference in the mean maximal percent fall in 
FEV1 was observed between treatment groups during the 
exercise challenge test conducted at Treatment Week 4 (Fig. 
2). The decrease in FEV1 observed was 9.9 ± 1.01% (mean ± 
standard error of the mean [SEM]) in the FSC 100/50 group 
compared with a decrease of 11.1 ± 1.02% in the FP 100 
group. Post-challenge these values fell to 2.02 ± 0.064 and 
1.99 ± 0.071 L for FSC 100/50 and FP 100, respectively. 
  Over the four-week treatment period, there were no 
significant changes in the AM or PM PEFs, or percentages 
of rescue free- or symptom-free days or 4-hour post-dose 
FEV1 between the groups. For AM PEF, a mean increase of 
23.7 ± 3.95 liters (L)/minute was seen compared to 14.2 ± 
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L/minute and 6.2 ± 3.70 L/minute were observed in PM PEF 
for the FSC 100/50 and FP 100 groups, respectively. For 
percentage of rescue-free days (days without inhaled 
albuterol treatment), a greater increase was seen in the FP 
100 group at 19.1 ± 3.92% compared to 16.9 ± 3.23% for the 
FSC 100/50 group. Similarly, the increase in percentage of 
symptom-free days favored FP 100 at 18.6 ± 4.11%, 
compared to 10.9 ± 3.19% for FSC 100/50. FEV1 AUC over 
4 hours on Treatment Day 1 was greater in the FSC 100/50 
group (0.72 ± 0.08 L/hr) compared to the FP 100 group (0.26 
± 0.05 L/hr). Comparison of treatment differences for all 
secondary endpoints was contingent upon obtaining a 
significant treatment difference for the primary measure of 
mean maximal percent fall in FEV1 following exercise 
challenge at Treatment Week 4. Since a significant treatment 
difference was not observed for the primary endpoint, all 
comparisons for the secondary measures were not considered 
statistically significant (Table 3). 
  Other measures of efficacy included the evaluation of a 
categorical treatment response evaluating the percentage of 
subjects who demonstrated a fall in FEV1 of <10%, a 10% to 
<20%, and a 20% following exercise challenge (Table 4). 
At Week  4, the  categorical treatment response for the 
exercise challenge test was similar between treatment   
 
 
Fig. (2). Mean maximal % fall in FEV1 after exercise challenge. 
groups. A total of 88 (88%) subjects in the FSC group had a 
<20% fall in FEV1 following the exercise challenge test, 
compared with 82 (81%) subjects in the FP group. A total of 
12 (12%) subjects in the FSC group had a 20% fall in FEV1 
following the exercise challenge test compared with 19 
(19%) subjects in the FP group. 
  The heart rate recovery time for FSC 100/50 and FP 100 
were 31.4 ± 2.60 (mean ± SEM) minutes and 30.8 ± 2.36 
Table 3.  Comparison of Other Efficacy Endpoints 
 
  FSC 100/50  FP 100 
Screening 
FEV1 pre-exercise, L   2.19 ± 0.696  2.19 ± 0.711 
Maximum fall in FEV1 post-exercise, %   -24.3 ± 10.87  -24.9 ± 10.27 
Post-Run-In (Pre-Randomization) 
FEV1 pre-exercise,   2.21 ± 0.720  2.21 ± 0.711 
Maximum fall in FEV1 post-exercise, %   -27.1 ± 7.77  -28.0 ± 8.59 
Morning PEF, L/minute   268.5 ± 9.14  274.2 ± 10.36 
Evening PEF, L/minute   286.6 ± 9.24  293.8 ± 10.78 
Albuterol-free days, %   36.5 ± 3.33  41.5 ± 3.54 
Symptom-free days, %   15.8 ± 2.24  18.0 ± 2.30 
Post Treatment (4 weeks)  
FEV1 pre-exercise, L   2.27 ± 0.073  2.24 ± 0.077 
Maximum fall in FEV1 post-exercise, %   -9.9 ± 1.01  -11.1 ± 1.02 (p=0.158) 
Morning PEF, L/minute   292.7 ± 9.57  290.4 ± 11.10 
Change from baseline of morning PEF, L/minute   23.7 ± 3.95  14.2 ± 4.45 (p=0.093) 
Evening PEF, L/minute   302.3 ± 9.70  297.3 ± 10.91 
Change from baseline of evening PEF, L/minute   14.3 ± 3.44  6.2 ± 3.70 (p=0.107) 
Albuterol-free days, %   53.4 ± 4.23  60.0 ± 3.91 
Change from baseline of % albuterol-free days  16.9 ± 3.23  19.1 ± 3.92 (p=0.256) 
Symptom-free days, %   27.2 ± 3.89  36.2 ± 4.00 
Change from baseline of % symptom-free days   10.9 ± 3.19  18.6 ± 4.11 (p=0.056) 
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minutes at screening and 31.1 ± 2.25 and 31.9 ± 2.33 
minutes pre-randomization, respectively (Table 5 ). In 
contrast, recovery times were shorter after 4 weeks of 
treatment at 14.5 ± 2.16 minutes and 12.7 ± 1.88 minutes for 
FSC 100/50 and FP 100, respectively (difference between 
treatments not significant, p=0.829). 
Table  4.  Categorical Treatment Responses After Exercise 
Challenge at Week 4 
 
 FSC  100/50  FP 100 
<10% Fall in FEV1 
Number of subjects  65  56 
Maximum fall in FEV1 post-exercise, %   -4.5 ± 0.49  -4.2 ± 0.46 
10% to <20% Fall in FEV1 
Number of subjects  23  26 
Maximum fall in FEV1 post-exercise, %  -14.0 ± 0.57  -14.0 ± 0.55 
20% Fall in FEV1  
Number of subjects  12   19 
Maximum fall in FEV1 post-exercise, %  -31.5 ± 2.97  -27.2 ± 2.37 
Maximum fall in FEV1 post-exercise data expressed as mean ± standard error of the 
mean. 
 
  Both treatments were well-tolerated and the incidence of 
adverse events (AEs) was similar across groups (n=20 or 
18% for FSC 100/50 and 25 or 21% for FP 100). The most 
common AEs were headache (11 total: 6 and 5 in subjects 
receiving FSC 100/50 and FP 100, respectively) and upper 
respiratory infection (5 total: 3 in FSC 100/50 group and 2 in 
the FP 100 group). Drug-related AEs were also comparable 
and infrequent (1 or <1% for FSC 100/50 and 3 or 3% for FP 
100). No individual AE considered to be drug-related 
exceeded 3% of the population. One subject in each group 
was withdrawn due to AEs, neither of which were deemed 
drug-related by the investigator. There were no serious AEs 
or fatal events. Three asthma exacerbations occurred during 
double-blind treatment (two in the FSC 100/50 group and 
one in the FP 100 group); all were either mild or moderate as 
determined by the investigator and all resolved by the end of 
the study. 
DISCUSSION 
  In this four-week, randomized, double-blind, parallel 
group, multi-center clinical trial utilizing exercise challenge, 
which followed a widely accepted and validated approach, 
both FSC 100/50 and FP 100 attenuated the fall in FEV1 
after exercise challenge. A statistical difference was not 
observed when the mean maximal percent falls between 
treatments were analyzed (p=0.158), unlike in the 
identically-designed replicate study reported by Pearlman 
and colleagues [9] (Fig. 3 ). Results of this study 
demonstrated a statistically significant difference between 
FSC 100/50 and FP 100 in a similar population (p=0.021). 
  The results of the current study highlight the potential 
difficulties that can be encountered in studies examining 
exercise- or activity-induced bronchoconstriction. One of 
these is the influence of study design when interpreting the 
clinical response to exercise. In our study, FSC was the test 
medication and FP served as the active control. Prior to 
randomization to study drug, all patients completed a two- to 
five-week run-in on open label FP and at the end of the run-
in period, had to demonstrate a fall 20% in FEV1 following 
an exercise challenge. At least two weeks prior, while on 
open label ICS, subjects had to demonstrate 15% fall in 
FEV1 following an exercise challenge. The rationale for this 
approach was to ensure that the study population was 
familiar with methodology used during an exercise challenge 
and to ensure that ICS alone did not adequately control 
asthma symptoms triggered by standardized exercise 
challenge. Previous studies have shown that ICS alone can 
attenuate the fall in FEV1 post exercise after a single dose 
[13,14] and that the effect attained by ICS plateaus after 
approximately two weeks of treatment and is relatively 
Table 5.  Heart Rates and Heart Rate Recovery Times at Screening, After Run-In (Pre-Randomization) and After Four Weeks of 
Treatment 
 
  FSC 100/50  FP 100 
Screening 
Heart rate after exercise challenge, beats/minute   171.2 ± 2.19  172.5 ± 1.69 
Change from pre-exercise, beats/minute   78.7 ± 2.57  79.2 ± 2.15 
Recovery time, minutes   31.4 ± 2.60  30.8 ± 2.36 
Pre-Randomization 
Heart rate after exercise challenge, beats/minute   175.0 ± 1.96  173.3 ± 1.64 
Change from pre-exercise, beats/minute   78.8 ± 2.38  77.2 ± 2.23 
Recovery time, minutes   31.1 ± 2.25  31.9 ± 2.33 
Post-Treatment (4 Weeks) 
Heart rate after exercise challenge, beats/minute   169.3 ± 2.23  169.0 ± 1.90 
Change from pre-exercise, beats/minute  72.2 ± 2.47  74.6 ± 2.20 
Recovery time, minutes   14.5 ± 2.16  12.7 ± 1.88 
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unchanged with further chronic dosing [6, 15-17]. Thus, the 
active control FP group was expected to demonstrate a 
similar decrease in FEV1 post-exercise challenge after four 
additional weeks of randomized treatment to ICS (FP) as 
was seen immediately prior to randomization while receiving 
the same dose of open-label FP. 
  The exact reason for the unexpected protective response 
to exercise following FP treatment during the study period 
remains unclear. It is possible that variation in the exercise 
load between exercise challenges contributed to the results. 
In exercise challenge studies of children and adolescents 
with asthma, Carlsen et al. reported mean maximum falls in 
FEV1 of 8.8% and 25.1% when the exercise load was 85% 
and 95%, respectively, of the calculated heart rate maximum 
[18]. Thus, a slight shift in the exercise load can dramatically 
shift the FEV1 response to exercise, and reduced efforts 
could account for diminished falls in FEV1 after exercise 
challenges. We hypothesize that the lack of difference seen 
in this study can be accounted for by more strenuous 
exercise efforts during the exercise challenges during 
screening and prior to randomization, but less strenuous 
efforts at the last post-treatment visit. 
  We believe this may have occurred based on the heart 
rate recovery times observed over the course of the study. 
Heart rates at completion of exercise and change from pre-
exercise were not different between groups, and were similar 
at screening, eligibility prior to randomization, and after four 
weeks of treatment. However, the recovery times observed 
were notably shorter after four weeks as compared to 
screening and pre-randomization. Thus, we believe subjects 
had a considerably reduced exercise load, i.e., were not 
“pushed as hard”, during the final exercise challenges and 
this contributed to the comparable results in the falls in post-
treatment FEV1 seen with the two treatments. 
  An alternative explanation for the improvement by FP in 
FEV1 attenuation following exercise challenge is that ICS 
adherence may have been inadequate prior to randomization. 
The protocol stipulated that subjects should have been using 
ICS for at least 4 weeks prior to screening. While a 
prescription or dispensing of an ICS can be documented, 
there is no method to confirm actual use of ICS. In addition, 
adherence studies confirm that on average, ICS adherence to 
prescribed use is less than 50% [19, 20]. If adherence to ICS 
continued to be sub-optimal during the run-in period, the 
screening exercise challenges would not reflect a population 
using ICS. Furthermore, it is known that adherence rates 
improve when randomized to study medication in a clinical 
trial [21]. In addition, the current study was a relatively 
short-term study, which would also benefit adherence to 
study mediation, since adherence rates in clinical studies are 
negatively correlated to the length of the study [22, 23]. 
Thus, it is possible to surmise that the study population was 
reasonably controlled by ICS alone, but that the study did 
not adequately ensure appropriate use of ICS prior to 
randomization. However, adherence rates reported in the 
current study (assessed according to drug accountability 
conducted by the site personnel at each study visit) were 
>95% as determined during the treatment phase of the study 
for both groups. 
  If the exercise challenges were not closely monitored and 
standardized during the study, or if ICS adherence prior to 
randomization was not adequate, then the study results are 
difficult to interpret. However, previous studies have shown 
LABA plus ICS to statistically significantly attenuate the fall 
in FEV1 compared with ICS alone for patients with chronic 
asthma and in whom symptoms are triggered by exercise [8, 
9, 13]. Unlike the current study, a replicate study confirmed 
a statistically significant improvement in EIB protection in 
children and adolescents using FSC compared with FP [9]. 
However, even in this study, questions were raised 
concerning adherence to study medications especially in the 
adolescent group which is known to be a high risk group for 
poor adherence. 
  In summary, it is clear that both FSC 100/50 and FP 100 
had a positive effect on attenuating the fall in FEV1 after 
exercise challenge in pediatric and adolescent subjects who 
 
Fig. (3). Mean maximum % fall in FEV1 post-exercise; panel A illustrates data from the current study (N.S. between groups) and panel B 
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required regular use of ICS for the treatment of persistent 
asthma. It is also clear that exercise studies represent unique 
challenges relative to standardization of exercise challenges 
and ensuring proper adherence to study medications. 
Therefore exercise studies must be carefully designed and 
closely monitored with consistent efforts produced to ensure 
that the test outcomes accurately inform on the defined 
objectives of the study. In this study, the full magnitude of 
the fall in FEV1 from what would have been expected 
appears to have been decreased by various study factors, and 
may have abrogated any difference produced by the 
treatment per se. 
CONCLUSION 
  At the end of treatment, both FSC and FP protected 
against a fall in FEV1 following exercise in patients who at 
baseline experienced 20% fall in FEV1 following exercise. 
There was no significant difference between FSC 100/50 and 
FP 100 in the mean maximal percent fall in FEV1 at the 
exercise challenge test conducted following four weeks of 
treatment. The responses to other efficacy measures were 
comparable between treatments. 
  Both study medications were well-tolerated over four 
weeks of treatment. FSC 100/50 had an adverse event profile 
comparable to that observed with FP 100 when used by 
subjects with persistent asthma who exhibit activity-induced 
bronchospasm. In some patients, therapy with FSC 100/50 
may offer additional benefit if exercise-induced asthma 
symptoms are not adequately controlled with FP alone. 
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ABBREVIATIONS 
AE =  Adverse  event 
AM =  Morning 
ANCOVA =  Analysis  of  covariance 
BID =  Twice  daily 
EIA =  Exercise-induced  asthma 
EIB =  Exercise-induced  bronchospasm 
FEV1  =  Forced expiratory volume in one second 
FP =  Fluticasone  propionate 
FSC  =  Fluticasone propionate and salmeterol  
     combination 
HFA =  Hydrofluoroalkane 
ICS =  Inhaled  corticosteroid 
ITT =  Intent-to-treat 
L =  Liters 
MDI =  Metered-dose  inhaler 
mcg =  Micrograms 
PEF =  Peak  expiratory  flow 
QoL  =  Quality of Life 
SEM  =  Standard error of the mean 
SD =  Standard  deviation 
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